Anastasia Madenidou
Anastasia is a Rheumatology trainee and a Clinical Research Fellow at the Centre of Musculoskeletal Research, University of Manchester. Her research work focuses on precision medicine strategies in lupus spectrum disorders. Anastasia is the Deputy Chair of the British Rheumatology Society Trainee Committee and a member of the Newsletter Sub-Committee.
| Type, n° | Date, time | Session | Author | Title |
|---|---|---|---|---|
| Oral 0234 | Friday, 02.06.2023 10:35 – 10:45 | Update on the treatment of scleroderma lung disease | Del Galdo, F (UK) | 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS |
| New recommendations for the treatment of systemic sclerosis including the first set of synthetic and biological targeted therapies. | ||||
| Oral 0235 | Friday, 02.06.2023 10:45 – 10:55 | Update on the treatment of scleroderma lung disease | Ross, L (Australia) | DEVELOPMENT AND PRELIMINARY VALIDATION OF THE NOVEL SCLERODERMA CLINICAL TRIALS CONSORTIUM ACTIVITY INDEX |
| The authors present a new disease activity measure index in systemic sclerosis. | ||||
| Poster 0223 | Friday, 02.06.2023 12:35 – 12:40 | People with burning vessels | Uchida, L (UK) | LONG-TERM SURVEILLANCE STUDY OF RITUXIMAB (MABTHERA)-TREATED PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA): RITUXIMAB SURVEILLANCE STUDY IN VASCULITIS (RIVAS) |
| Over 60% of patients with GPA/MPA experienced an adverse event in their disease course. Rituximab did not increase the risk of experiencing a first adverse event but the time to second safety event was shorter in the rituximab group. | ||||
| Oral 0013 | Wednesday, 31.05.2023 15:20 – 15:30 | Precision medicine in SLE: where are we? | DybalI, S (UK) | APPLYING STANDARD CLASSIFICATION CRITERIA EXCLUDES UP TO A HALF OF ALL PATIENTS FROM CONNECTIVE TISSUE DISEASES (CTD) CLINICAL TRIALS |
| 195/391 (49.9%) patients of an unselected cohort of CTD patients would not be eligible for recruitment to a phase III trial, based on the physician diagnosis, and trial eligibility criteria. | ||||
| Poster 0955 | Thursday 01.06.2023 14:45 – 15:45 | Epidemiology, risk factors for disease or disease progression | Sieiro Santos, C (Spain) | PREGNANCY IN CONNECTIVE TISSUE DISEASES: A 30 YEAR FOLLOW-UP STUDY OF 465 PREGNANCIES FROM A SPANISH MONOCENTRIC REGISTRY |
| Patients with lupus had higher rates of fetal and maternal morbidity than SSc, pSS and UCTD. Disease activity was associated with unfavourable pregnancy outcomes, whereas exposure to HCQ had a protective effect. | ||||
| Oral 0117 | Thursday 01.06.2023 11:25-11:35 | Pathogenic clues to systemic sclerosis and myositis | Debrut, L (France) | PROTEASOME INHIBITION AS A NEW TREATMENT FOR DERMATOMYOSITIS: RESULTS OF A DRUG REPURPOSING ANALYSIS BASED ON THE TRANSCRIPTOMIC SIGNATURE OF PATIENTS’ PERIFASCICULAR FIBERS VALIDATED IN PRE-CLINICAL MODELS |
| Proteasome inhibition could be a new effective treatment strategy for dermatomyositis. | ||||